Akebia Therapeutics Inc. (AKBA) had a good day on the market for Friday November 29 as shares jumped 13.33% to close at $6.29. About 3.82 million shares traded hands on 13,219 trades for the day, compared with an average daily volume of n/a shares out of a total float of 118.86 million. After opening the trading day at $5.60, shares of Akebia Therapeutics Inc. stayed within a range of $6.56 to $5.51.
With today’s gains, Akebia Therapeutics Inc. now has a market cap of $747.65 million. Shares of Akebia Therapeutics Inc. have been trading within a range of $10.45 and $2.99 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.
Akebia Therapeutics Inc. is based out of Cambridge, MA and has some 325 employees. Its CEO is John P. Butler.
